medigraphic.com

2007, Number 4

<< Back

Bioquimia 2007; 32 (4)

Urinary citrate and urinary oxalate in adult patients with urolithiasis

Villanueva-Jorge S, Medina-Escobedo M, Arcos-Díaz A, Martín-Soberanis G

Language: Spanish
References: 20
Page: 134-140
PDF size: 125.73 Kb.


ABSTRACT

Urinary calculi formation is mostly due to the existence of metabolic alterations, such as hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia, and hypomagnesuria. Oxalates in urine promote the creation of calculi, and amongst the urinary inhibitors, like citrate reduces the supersaturation of urine. Hence, it is important to know the urinary excretion of both oxalates and citrates in 24-hour urine. We were studied men and women aged 18 years and older, with urinary lithiasis confirmed by ultrasonography or radiography; patients with other associated diseases were discarded. Oxalates and citrates were determined in urinary collection of 24-hour in all patients. Oxalates were determined by enzymatic-colourimetric reactions, and the UV kinetic enzymatic method was used for citrates determination; both determinations were carried out in a SPEC-310 spectrophotometer. Results were obtained through descriptive statistics. A total number of 173 patients, 59 men (32.7%) and 114 women (65.89%), were included. Citrate excretion rate was 311 ± 223 mg/dL, and 63.6% had hypocitraturia. Oxalate excretion rate was 37 ± 16mg/dL. Hypocitraturia was observed in 79.7% and 55.3% of men and women, respectively. In conclusion the urinary excretion of citrates in the studied sample is greater than referred by other authors.


REFERENCES

  1. Medina-Escobedo M, Zaidi M, Real-de León Q, Orozco-Rivadeneyra S. Prevalencia y factores de riesgo en Yucatán, México, para litiasis urinaria. Salud Pública Mex. 2002; 44: 541-5.

  2. Atilano X, Espinosa MA. Aspectos nutriológicos en la litiasis renal: relevancia de otros nutrimentos diferentes al calcio. Nut Clin. 2003; 6: 270-82.

  3. Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int. 2004; 66: 1159-66.

  4. Estrada-Jasso D, Martínez-Torres J, Cruz L. Litiasis urinaria en la atención primaria. Rev Fac Med UNAM. 2005; 48: 187-90.

  5. Lancina JA, Novas S, Rodríguez-Rivera J, Suares G, Blanco A, González M. Lithogenic metabolic profile related to gender in patients with calcium-containing urinary stones. Braz J Urol. 2001; 27: 423-31.

  6. Areses R, Urbieta MA, Ubetagoyena M, Mingo T, Arruebarrena D. Evaluación de la enfermedad renal litiásica: estudio metabólico. An Pediat. 2004; 61: 418-27.

  7. Robertson W, Rutherford A. Aspects of the analysis of oxalate in urine: a review. Danielson BG. (Ed). Proceedings of the symposium on urolithiasis. Sweden: Wellcome; 1979. p. 85-93.

  8. Bijan S. Hiperoxaluria. Disponible en: URL: http://www. emedicine.com/med/topic3027.htm, (consultado 23 de julio 2007).

  9. Borrero J. Enfermedad tubulointersticial. En: Borrero J, Montero O. (Eds). Fundamentos de Medicina; Nefrología. 4ª ed. Colombia: Corporación para investigaciones Biológicas; 2003. p. 527-31.

  10. Peña JC. Trastornos del equilibrio ácido básico. En: Peña JC. (ed.) Manual de nefrología y trastornos de agua y electrolitos. México: Interamericana; 2005. p. 240-68.

  11. Llamazares L, Rodríguez M, Gonzalez C, Blanco ML. Efecto del uso de conservador antes o después de la colección urinaria de 24 horas sobre la cuantificación de diferentes analitos. Bioquimia. 2007; 32: 10-4.

  12. Oxalato; Procedimiento Nº 591; Trinity biotech: pp.1-s: revisado febrero 2003. Disponible en: URL: http://www.trinitybiotech. com/Products/List/?prodid=816, (consultado 24 de julio 2007).

  13. AccumarkTM controls; control-E de oxalato en orina. Trinity biotech. Disponible en: URL: http://www.trinitybiotech. com/Products/List/?prodid=821 (consultado 24 de julio 2007).

  14. AccumarkTM controls; control N de oxalato en orina. Trinity biotech. Disponible en: URL: http://www.trinitybiotech. com/Products/List/?prodid=822 (consultado 24 de julio 2007).

  15. Citric acid; Cat. No 10139076035; Boehringer Mannheim r-Biopharm; Roche (inserto de reactivo).

  16. Deshmukh S, Khan Z. Evaluation of urinary abnormalities in nephrolithiasis patients from Marathwada region. Ind J Clinic Biochemistry. 2006; 21: 177-80.

  17. Patiño S, Abitbol M, Rodríguez N, Pérez R. Perfil metabólico urinario del paciente con litiasis urinaria. Rev Postgrado Vía Cátedra de Med. 2005; 146: 10-2.

  18. Tamayo JA, Peña JC. Diagnóstico, prevención y tratamiento de la litiasis renal y de vías urinarias. Gac Med Méx. 1990; 126: 497-507.

  19. Yuji k, Satoshi Y, Sunao Y, Shusaku N, Jun-Ichi H, Naoki W, et al. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology. 2004; 63: 7-12.

  20. Trinchieri A, Lizzano R, Marchesotti F, Zanetti G. Effect of potential renal acid of foods on urinary citrate excretion in calcium renal stone formers. Urol Res. 2006; 343: 1-7.




2020     |     www.medigraphic.com